RIVAL-01

N/A

Report date: 2025/04/24 20:00:10

Base Information

Drug NameRIVAL-01
Drug Alias NameTBio-6517TAK-605
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsTyrosine-protein kinase receptor FLT3 stimulantsImmunostimulants +[5] 
TargetsTyrosine-protein kinase receptor FLT3Interleukin-12 receptorCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSkin MelanomaSolid tumoursUterine Cervical Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTurnstone Biologics CorpTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTurnstone Biologics CorpTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSkin MelanomaSolid tumoursUterine Cervical Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A